Published in Stroke on January 27, 2005
The promise and potential pitfalls of serum biomarkers for ischemic stroke and transient ischemic attack. Neurologist (2008) 0.86
Lack of evidence of CD40 ligand involvement in transfusion-related acute lung injury. Clin Exp Immunol (2011) 0.85
CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther (2015) 0.83
Association between Serum Soluble CD154 Levels and Mortality in Patients with Malignant Middle Cerebral Artery Infarction. Int J Mol Sci (2015) 0.77
Platelet activation in obese women: role of inflammation and oxidant stress. JAMA (2002) 2.79
POINT: Efficacy of adding mitral valve restrictive annuloplasty to coronary artery bypass grafting in patients with moderate ischemic mitral valve regurgitation: a randomized trial. J Thorac Cardiovasc Surg (2009) 2.28
[Takotsubo cardiomyopathy: a consensus document]. G Ital Cardiol (Rome) (2008) 2.26
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J Am Coll Cardiol (2009) 2.11
Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy. J Am Coll Cardiol (2013) 2.05
Asymptomatic carotid lesions and aging: Role of hypertension and other traditional and emerging risk factors. Arch Med Res (2006) 2.03
Deep venous thrombosis and previous myocardial infarction in mild factor XII deficiency: a risk factor for both venous and arterial thrombosis. J Thromb Thrombolysis (2008) 1.96
Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med (2007) 1.88
Impact of moderate ischemic mitral regurgitation after isolated coronary artery bypass grafting. Ann Thorac Surg (2010) 1.77
Chronic pharmacological treatment in takotsubo cardiomyopathy. Int J Cardiol (2007) 1.73
Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med (2007) 1.67
VEGF-A gene promoter polymorphisms and microvascular complications in patients with essential hypertension. Clin Biochem (2010) 1.48
An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb (2009) 1.44
Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol (2003) 1.39
Pentraxin 3 and Platelet Activation in Obese Patients After Gastric Banding. Circ J (2015) 1.39
Neuromuscular disorders and non compaction: how much is the strength of the association and how can it be suspected? Int J Cardiol (2008) 1.39
Asymptomatic ventricular pre-excitation in children. J Cardiovasc Med (Hagerstown) (2009) 1.39
Lipid peroxidation in diabetes mellitus. Antioxid Redox Signal (2005) 1.37
Soluble forms of RAGE in internal medicine. Intern Emerg Med (2009) 1.28
Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab (2003) 1.22
Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol (2009) 1.22
Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation (2009) 1.19
Segmental dyskinesia in Wolff-Parkinson-White syndrome: a possible cause of dilatative cardiomyopathy. Int J Cardiol (2007) 1.18
Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem (2009) 1.18
Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation (2003) 1.16
Soluble CD40 ligand plasma levels in lung cancer. Clin Cancer Res (2004) 1.15
Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation (2002) 1.09
Increased circulating Interleukin-18 levels in centenarians with no signs of vascular disease: another paradox of longevity? Exp Gerontol (2003) 1.07
Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study. Stroke (2005) 1.06
Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med (2003) 1.04
Diabetes mellitus and thrombosis. Thromb Res (2011) 1.04
Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. Circulation (2012) 1.03
Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol (2006) 1.00
Inflammation, insulin resistance, and obesity. Curr Atheroscler Rep (2004) 0.98
Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol (2005) 0.97
Cardiopulmonary Exercise Testing in Patients with Chronic Heart Failure: Prognostic Comparison from Peak VO2 and VE/VCO2 Slope. Open Cardiovasc Med J (2010) 0.95
Platelet activation, inflammatory mediators and hypercholesterolemia. Curr Vasc Pharmacol (2003) 0.95
Anticoagulant drugs in noncompaction: a mandatory therapy? J Cardiovasc Med (Hagerstown) (2008) 0.95
Biomarkers of platelet activation in acute coronary syndromes. Thromb Haemost (2012) 0.94
Urinary excretion of lipoxin A(4) and related compounds: development of new extraction techniques for lipoxins. Lab Invest (2002) 0.94
Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response. FASEB J (2010) 0.93
Contrast-induced nephropathy after percutaneous coronary intervention in simple lesions: risk factors and incidence are affected by the definition utilized. Intern Med (2011) 0.92
Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem Phys Lipids (2004) 0.92
Off-pump versus on-pump myocardial revascularization in patients with ST-segment elevation myocardial infarction: a randomized trial. J Thorac Cardiovasc Surg (2009) 0.92
Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients. Atherosclerosis (2010) 0.92
Role of NADPH oxidase in atherosclerosis. Future Cardiol (2009) 0.92
Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonography. Clin Rheumatol (2007) 0.92
Preclinical atherosclerosis and metabolic syndrome increase cardio- and cerebrovascular events rate: a 20-year follow up. Cardiovasc Diabetol (2013) 0.90
A novel flow cytometric approach to distinguish circulating endothelial cells from endothelial microparticles: relevance for the evaluation of endothelial dysfunction. J Immunol Methods (2012) 0.89
Relative chemokine and adhesion molecule expression in Mediterranean spotted fever and African tick bite fever. J Infect (2008) 0.88
Papillary muscle relocation in conjunction with valve annuloplasty improve repair results in severe ischemic mitral regurgitation. J Thorac Cardiovasc Surg (2011) 0.88
Platelet function in health and disease: from molecular mechanisms, redox considerations to novel therapeutic opportunities. Antioxid Redox Signal (2012) 0.88
Aging is characterized by a profound reduction in anti-inflammatory lipoxin A4 levels. Exp Gerontol (2005) 0.88
Autonomic dysfunction and microvascular damage in systemic sclerosis. Clin Rheumatol (2007) 0.87
Superficial venous thrombosis: prevalence of common genetic risk factors and their role on spreading to deep veins. Thromb Res (2008) 0.87
Magnetic resonance in isolated noncompaction of the ventricular myocardium. Int J Cardiol (2008) 0.87
Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. Thromb Haemost (2003) 0.87
High resolution ultrasonography in detection of bone erosions in patients with hand osteoarthritis. J Rheumatol (2005) 0.86
NOX2 up-regulation is associated with artery dysfunction in patients with peripheral artery disease. Int J Cardiol (2012) 0.86
Prognostic value of soluble P-selectin levels in colorectal cancer. Int J Cancer (2004) 0.86
CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke. J Atheroscler Thromb (2009) 0.86
Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and low-dose aspirin. Circulation (2003) 0.85
Platelet isoprostane overproduction in diabetic patients treated with aspirin. Diabetes (2012) 0.85
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. Blood (2008) 0.85
Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis (2010) 0.85
The PFO anatomy evaluation as possible tool to stratify the associated risks and the benefits arising from the closure. Eur J Echocardiogr (2010) 0.84
Serum VEGF and b-FGF profiles after tension-free or conventional hernioplasty. Langenbecks Arch Surg (2005) 0.84
Atherosclerosis, inflammation and Chlamydia pneumoniae. World J Cardiol (2009) 0.84
Nutrition, supplements, and vitamins in platelet function and bleeding. Circulation (2010) 0.84
Isoprostane formation and inhibition in atherothrombosis. Curr Opin Pharmacol (2005) 0.84
Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol (2006) 0.83
Helicobacter pylori and atrial fibrillation: absence of correlations. J Cardiovasc Med (Hagerstown) (2009) 0.83
Peripheral artery disease: potential role of ACE-inhibitor therapy. Vasc Health Risk Manag (2008) 0.83
Markers of inflammation are strong predictors of subclinical and clinical atherosclerosis in women with hypertension. Coron Artery Dis (2009) 0.83
Ascorbic acid infusion blunts CD40L upregulation in patients undergoing coronary stent. Cardiovasc Ther (2010) 0.83
Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype. J Am Heart Assoc (2013) 0.83
ICD implantation in noncompaction of the left ventricular myocardium: a case report. Pacing Clin Electrophysiol (2009) 0.83
Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes Metab Res Rev (2008) 0.83
Determinants of platelet activation in Alzheimer's disease. Neurobiol Aging (2006) 0.83
Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients. Free Radic Biol Med (2012) 0.83